云顶新耀维适平 获国家药监局批准上市 开启中重度溃疡性结肠炎口服新时代

Core Insights - The approval of VELSIPITY (Arginine Eculizumab Tablets) by the NMPA marks a significant advancement in the treatment of moderate to severe active ulcerative colitis (UC) in adults, addressing a critical gap in the market for patients unresponsive to traditional therapies [1][2][4] Group 1: Product Overview - VELSIPITY is a next-generation high-selectivity S1P receptor modulator, designed for once-daily oral administration, offering rapid onset and effective deep mucosal healing, with a strong safety profile [1][3] - The drug is projected to reach peak sales of 5 billion RMB, positioning it as a core product for the company following its success with renal disease treatment [1][6] Group 2: Market Context - The incidence of ulcerative colitis in China is rising, with an expected increase in patient numbers from approximately 980,000 in 2025 to about 1.5 million by 2031, highlighting the urgent need for effective treatments [2] - Current treatment options are limited, with existing therapies facing challenges such as limited efficacy, high relapse rates, and adverse reactions [2][5] Group 3: Clinical Efficacy - Clinical trials have demonstrated VELSIPITY's significant efficacy, with a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% over 40 weeks of maintenance treatment [3][4] - The drug has been recognized in multiple international guidelines as a first-line treatment for ulcerative colitis, underscoring its clinical value [4] Group 4: Commercialization Strategy - The company has established a comprehensive A2MS operational system to facilitate the market entry of VELSIPITY, leveraging its scientific and commercial insights [5][6] - VELSIPITY is set to be included in the urgent import drug directory for clinical use in the Greater Bay Area in 2024, providing a first-mover advantage [6][7] Group 5: Financial Outlook - The approval of VELSIPITY enhances the company's revenue structure, with expectations of significant growth in revenue and profitability as it expands its product portfolio [6][7] - The company aims to achieve over 15 billion RMB in revenue by 2030, driven by a combination of existing and new product sales, with a projected compound annual growth rate exceeding 50% from 2025 to 2030 [7]